Overall trial status: Ended
Trial title: A multicenter, Phase 1b, double-blind, placebo-controlled study to evaluate the safety and tolerability, and the efficacy of si-544 in adults with psoriasis vulgaris or psoriatic arthritis
Medical conditions: psoriasis vulgaris, psoriatic arthritis
Status in each country: Germany:Ended
Trial phase: Human Pharmacology (Phase I)- Other
Therapeutic Areas: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Primary end point: N/A
Secondary end point: N/A
Age of participants: 65+ years, 18-64 years
Gender of participants: Female, Male
Trial region: EEA only
Planned number of participants: 45
Sponsor: selectION Therapeutics GmbH
Sponsor type: Pharmaceutical company
Trial product: N/A
Results posted: No
Overall decision date: 07/12/2023
Countries decision date: DE: 07/12/2023
Last updated date: 13/05/2025
Es gibt noch keine Rezensionen.